ArticleTranslational cancer research2025
Screening of PANoptosis regulator-associated long noncoding RNAs and construction of a survival prognostic model in cutaneous melanoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cutaneous melanoma (SKCM) remains a lethal malignancy with complex molecular mechanisms. PANoptosis, a coordinated cell death pathway, and long noncoding RNAs (lncRNAs) have emerged as critical modulators influencing oncogenic pathways and tumor development through multifaceted regulatory mechanisms. This study aimed to identify PANoptosis regulator (PANR)-associated lncRNAs and construct a prognostic model to predict SKCM outcomes and to clarify their associations with immune infiltration, drug sensitivity, and molecular pathways. Methods: Gene expression data from 471 The Cancer Genome Atlas (TCGA)-human skin SKCM tumors, 214 Gene Expression Omnibus-SKCM samples, and 812 Genotype-Tissue Expression normal tissues were merged after batch correction. A PANR set (n=300) was integrated to identify differentially expressed PANRs (DE-PANRs) and identify differentially expressed lncRNAs (DE-lncRNAs) using the "limma" package [false discovery rate (FDR) <0.05 and |log Results: Differential analysis identified 995 DE-lncRNAs and 142 DE-PANRs, with 83 PANR-associated lncRNAs forming a regulatory network. Six prognostic lncRNAs (MIR155HG, LINC01501, NRIR, HLA-DQB1-AS1, USP30-AS1, and LINC00674) were optimized via LASSO. Survival disparities were observed between the high- and low-risk cohorts stratified by the RS model [TCGA cohort: hazard ratio (HR) =2.72, P<0.001; GSE65904 cohort: HR =1.85, P=0.002]. The nomogram integrating RS, age, and tumor stage could predict the 1-, 3-, and 5-year survival (concordance index =0.81). High-risk patients exhibited immunosuppressive profiles and showed differential drug response patterns, with predicted increased sensitivity to 14 therapeutic agents. Enriched pathways included apoptosis, inflammatory response, and KRAS signaling. Mutational analysis revealed the top 20 mutated genes that differed the most between risk groups. Conclusions: This study established a PANR-associated lncRNA prognostic model with robust predictive accuracy for SKCM survival. The risk stratification system correlates with immune dysregulation, therapy response, and pathway activation, offering a potential tool for personalized prognosis and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.